News
INMB
11.63
-2.10%
-0.25
Earnings Scheduled For March 28, 2024
Universal Stainless is expected to report quarterly earnings at $0.32 per share on revenue of $78.65 million. Walgreens Boots Alliance is likely to report earnings for its fourth quarter. Companies Reporting Before The Bell include Shimmick and Universal Stainless. Companies reporting after the bell include INmune Bio and Oxford Industries.
Benzinga · 2h ago
Notable earnings after Thursday's close
Major earnings expected after the bell on Thursday include: Vuzix Corporation, Emeren Group Ltd. Other major earnings slated for release after Thursday's close include: Energous Corporation and Planet Labs. For the full earnings season calendar, visit Seeking Alpha's earnings calendar.
Seeking Alpha · 14h ago
A Preview Of INmune Bio's Earnings
INmune Bio is set to give its latest quarterly earnings report on Thursday, 2024-03-28. Analysts estimate the company will report an earnings per share of $-0.44. Last quarter the company missed EPS by $0.07. Shares of INmune bio were trading at $11.88 as of March 26.
Benzinga · 18h ago
Weekly Report: what happened at INMB last week (0318-0322)?
Weekly Report · 2d ago
Weekly Report: what happened at INMB last week (0311-0315)?
Weekly Report · 03/18 12:29
Weekly Report: what happened at INMB last week (0304-0308)?
Weekly Report · 03/11 12:23
Buy Rating Affirmed for Inmune Bio Amid Promising Alzheimer’s Treatment Developments
TipRanks · 03/06 18:56
INmune Bio Reports Significant EEG Improvement In Alzheimer's Patients Treated With XPro
Patients with Alzheimer's Disease show improvement in brainwaves following 4 weeks of XPro™ therapy. INmune Bio, Inc. Reports significant improvements in electroencephalography (EEG) in patients with moderate to severe Alzheimer's disease treated with XPro for four weeks. Alpha wave frequency and power is linked with cognitive decline and the progression of the disease. XPro is a next generation inhibitor of TNF.
Benzinga · 03/05 13:02
Weekly Report: what happened at INMB last week (0226-0301)?
Weekly Report · 03/04 12:28
Weekly Report: what happened at INMB last week (0219-0223)?
Weekly Report · 02/26 12:49
Weekly Report: what happened at INMB last week (0212-0216)?
Weekly Report · 02/19 12:51
Weekly Report: what happened at INMB last week (0205-0209)?
Weekly Report · 02/12 12:34
INmune Bio to Participate in Baird’s Biotech Discovery Series Webcast on February 13, 2024
INmune Bio, Inc. Is a clinical-stage immunology company targeting microglial activation and neuroinflammation as a cause of Alzheimer's disease. Management will participate in Baird’s Biotech Discovery Series webcast on February 13, 2024 at 10:30am EST.
Barchart · 02/06 08:00
Weekly Report: what happened at INMB last week (0129-0202)?
Weekly Report · 02/05 12:48
BTIG Remains a Buy on Inmune Bio (INMB)
TipRanks · 02/02 10:25
Buy Rating Affirmed: Inmune Bio’s XPro Progresses with FDA’s Green Light and Unique Therapeutic Approach
TipRanks · 02/01 05:37
Inmune Bio’s Buy Rating Affirmed Amid Positive Alzheimer’s Program Developments
TipRanks · 01/31 17:35
Inmune Bio Resumes Alzheimer’s Trial, Aims for Mid-2024 Enrollment
TipRanks · 01/31 09:07
U.S. RESEARCH ROUNDUP- Advanced Micro Devices, HCA Healthcare, Vertex Pharmaceuticals
Wall Street analysts revise their ratings and price targets on several U.S.-listed companies. Advanced Micro Devices, HCA Healthcare, Vertex Pharmaceuticals among companies with new targets. Some analysts raised their targets on Wednesday. Others cut their targets for the companies, which include Alphabet and HCA.
Reuters · 01/31 07:16
FDA Lifts Clinical Hold on INmune Bio Alzheimer's Program
FDA lifts full clinical hold on immunology company's Alzheimer's disease program. INmune Bio says a Phase 2 study using its XPro product candidate is on track to enroll its last patient in mid-2024. The FDA implemented the clinical hold in May 2022.
Dow Jones · 01/30 13:27
More
Webull provides a variety of real-time INMB stock news. You can receive the latest news about Inmune Bio Inc through multiple platforms. This information may help you make smarter investment decisions.
About INMB
INmune Bio, Inc. is a clinical-stage biotechnology pharmaceutical company. The Company is focused on developing and commercializing its product candidates to treat diseases where the innate immune system is not functioning normally and contributing to the patient’s disease. Its drug candidates include INKmune, INB03, and XPro1595 (XPro). It has two product platforms. The DN-TNF product platform utilizes dominant-negative technology to selectively neutralize soluble tumor necrosis factor alpha (TNF), a driver of innate immune dysfunction and mechanistic target of many diseases. DN-TNF is being developed for Alzheimer’s and treatment resistant depression (XPro) and cancer (INB03). The Natural Killer (NK) Cell Priming Platform includes INKmune for priming the patient’s NK cells to eliminate minimal residual disease in patients with cancer. Its product platforms utilize a precision medicine approach for the treatment of hematologic malignancies, solid tumors, and chronic inflammation.